A phase II/III, randomized, double-blind, placebo-controlled trial to evaluate immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in the prophylactic treatment for SARS-СoV-2 infection in the United Arab Emirates

A phase II/III, randomized, double-blind, placebo-controlled trial to evaluate immunogenicity and safety of the Gam-COVID-Vac combined vector vaccine in the prophylactic treatment for SARS-СoV-2 infection in the United Arab Emirates

Background: Long-term efficacy and safety profiles of the various SARS-CoV-2 vaccines were investigated. Current trial aimed to assess the safety and immunogenicity of the Gam-COVID-Vac combined vector vaccine against SARS-CoV-2-induced coronavirus infection up to 6 months post vaccination. Research...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmed A.K. AlHammadi, Amna H. Alzaabi, Haneen B. Choker, Ahmed A. Ibrahim, Asma Bin Ishaq, Ahmed E. Mahboub, Reem S. Al Dhaheri, Mohamed N. Alzaabi, Timothy A. Collyns, Gehad ElGhazali, Stefan Weber, Basel K. Al-Ramadi
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Vaccine: X
Subjects:
COVID-19
Randomized control trial
Vector
Adenoviral vector vaccine
Sputnik V
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136225000920
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2590136225000920

Similar Items